"Actually, we have a very limited, but we think exciting piece of data that says that it (ddRNAi) might be efficacious .... we have the opportunity to use now ddRNAi in combination or alone, as a stand alone technology for long term treatment of HIV infection and I see that this is something that really needs to be exploited"
John Rossi speaking about the Phase I HIV clinical trial.
Sounds to me like some of the additional patients are being dosed with ddRNAi alone. Or am I just reading too much into this? What will happen to BLT's share price when they publish this piece of data they have from the original trial? A trial which incidentially, BLT own the rights too.
- Forums
- ASX - By Stock
- BLT
- will it close out with
will it close out with, page-22
-
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online